Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones January 8, 2024 CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists - Read More December 6, 2023 CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023 - Read More October 31, 2023 CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers - Read More Load MoreLoadingMeet us at the following conferences & events ESMO I-O Congress 2023 Dec 6 - Dec 8, 2023 Geneva, Switzerland Read More JPM 2024 Jan 8 -Jan 11, 2024 San Francisco, CA, USA Read More IO 360° 2024 Feb 27 - Feb 29, 2024 New York, NY, USA Read More ASCO 2024 May 31 - June 4, 2024 Chicago, IL, USA Read More
